Skip to main content

Advertisement

Log in

Imatimid-induced bone marrow necrosis detected on MRI examination and mimicking bone metastases

  • Case Report
  • Published:
Skeletal Radiology Aims and scope Submit manuscript

Abstract

Imatinib has revolutionized the treatment and prognosis of patients with gastrointestinal stromal tumors (GIST). In contrast to liver and/or abdominal involvement, bone metastases are an uncommon event in GIST. We report here two patients with metastatic GIST who developed pelvic bone marrow focal lesions visible on MRI examinations, while Imatinib dramatically improved other tumor sites. A biopsy in one patient diagnosed bone marrow necrosis. The other patient had a favorable follow-up over several years, without bone metastases. Focal bone marrow abnormalities, detected on MRI examinations and mimicking bone metastases in patients who were otherwise responding, should be considered as probable bone marrow necrosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998;11: 728–734.

    PubMed  CAS  Google Scholar 

  2. De Mestier P, Guetz GD. Treatment of gastrointestinal stromal tumors with imatinib mesylate: a major breakthrough in the understanding of tumor-specific molecular characteristics. World J Surg 2005;29: 357–361.

    Article  PubMed  Google Scholar 

  3. Ray-Coquard J, Le Cesne A, Blay JY. STI571 and gastrointestinal stromal tumors. Bull Cancer 2001;88: 661–662.

    PubMed  CAS  Google Scholar 

  4. Choi H. Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model. Curr Oncol Rep 2005;7: 307–311.

    Article  PubMed  Google Scholar 

  5. Padhani AR, Ollivier L. The RECIST criteria: implications for diagnostic radiologists. Br J Radiol 2001;74 :983–986.

    PubMed  CAS  Google Scholar 

  6. Vanel D, Albiter M, Shapeero LG, et al. Role of computed tomography in the follow-up of hepatic and peritoneal metastases of GIST under imatinib mesylate treatment: a prospective study of 54 patients. Eur J Radiol 2005;54: 118–123.

    Article  PubMed  Google Scholar 

  7. Matsue K, Takeuchi M, Koseki M, Uryu H. Bone marrow necrosis associated with the use of imatinib mesylate in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Hematol 2006;85: 542–544.

    Article  PubMed  Google Scholar 

  8. Tamura T, Tasaka T, Fujimoto M, Matsuhashi Y, Fukumot T, Mano S, Kuwajima M, Nagai M. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy. Haematologica 2004;89:ECR32.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to D. Vanel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vanel, D., Bonvalot, S., Pechoux, C.L. et al. Imatimid-induced bone marrow necrosis detected on MRI examination and mimicking bone metastases. Skeletal Radiol 36, 895–898 (2007). https://doi.org/10.1007/s00256-007-0344-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00256-007-0344-0

Keywords

Navigation